scholarly journals Estimation of Average Blood Glucose Values Based on Fructosamine Values

2021 ◽  
Author(s):  
Luis Jesuino de Oliveira Andrade ◽  
Alcina Maria Vinhaes Bittencourt ◽  
Luiz Felipe Moreno de Brito ◽  
Luis Matos de Oliveira ◽  
Gabriela Correia Matos de Oliveira
Keyword(s):  
Linear Regression Analysis ◽  
Coefficient Of Determination ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Lower Case ◽  
Capillary Glucose ◽  
Average Blood Glucose ◽  
Average Glucose

Introduction: The fructosamine is originated of the glycation of plasmatic proteins, especially albumin, in addition to immunoglobulins and proteins diverse. It constitutes an alternative biomarker of glycemic control when glycated hemoglobin is not indicated for this purpose. Objective: To define the mathematical relationship between fructosamine and average glucose values. Method: The study comprised the laboratorial data collected of 1227 diabetic subjects (type 1 and type 2). Fructosamine levels obtained at the end of three weeks and measured were compared with the average glucose levels of the three previous weeks. The average glucose levels were determined by the weighted mean of the daily fasting capillary glucose results performed during the study period, and the plasma glucose taken at the time of the fructosamine. Results: A total of 9,450 glucoses were performed. Linear regression analysis between the fructosamine and average glucose levels showed that each increase of 1.0 lower case Greek mumol/L in fructosamine increase 0.5mg/dL in the average glucose levels as evidenced in the equation forward: Average glucose levels = 0.5157 x Fructosamine - 20. According to the coefficient of determination (r2 = 0.353492, P < 0.006881), making it possible to calculate the estimated average glucose according to the frutosamine values. Conclusion: Fructosamine levels can be expressed as average glucose levels for assessing the metabolic control of diabetic patients.

Diabetes mellitus

2020 ◽  
pp. 373-396
Author(s):  
Charlotte Frise ◽  
Sally Collins
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Postnatal Care ◽  
Glucose Monitoring ◽  
Pregnant Patient ◽  
Monogenic Diabetes ◽  
Glucose Levels ◽  
Capillary Glucose

This chapter covers all issues of diabetes mellitus in relation to pregnancy. Type 1 and type 2 diabetes are defined, alongside gestational and monogenic diabetes. Advice for the pregnant patient with diabetes is given for every stage, from preconception to ante- and postnatal care. Practical aspects such as target capillary glucose levels, glucose monitoring, and types of insulin are all described. Complications and emergencies, including hypoglycaemia and diabetic ketoacidosis, are also explained, along with their management.

scholarly journals Euglycemic ketoacidosis complicating empagliflozin therapy in a Bangladeshi type 2 diabetic lady

2021 ◽  
Vol 11 (3) ◽  
pp. 243-245
Author(s):  
Rezwana Laboni ◽  
Faria Afsana ◽  
Kazi Nazmul Hossain ◽  
Rushda Sharmin Binte Rouf ◽  
Mohammod Feroz Amin ◽  
...  
Keyword(s):  
Ketone Bodies ◽  
Diabetic Patients ◽  
Serum Bicarbonate ◽  
Diagnostic Challenge ◽  
Type 2 Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Type 2 Diabetic

Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, which may occurin both type 1 and type 2 diabetic patients. It is characterized by hyperglycaemia [blood glucose levels > 250 mg/dL (13.8 mmol/ L)], metabolic acidosis (pH <7.3 or serum bicarbonate <15 mmol/L) with an increased anion gap and the presence of ketone bodies in blood or urine. A subgroup of patients may present without signs of hyperglycemia, rather present with euglycemia, posing a diagnostic challenge due to the absence of the cardinal findings of the pathophysiology in DKA. Here, we report a case of euglycemic ketoacidosis complicating a 50-year-old Bangladeshi diabetic lady receiving empagliflozin treatment. BIRDEM Med J 2021; 11(3): 243-245

scholarly journals NETosis contributes to the pathogenesis of diabetes and its complications

2020 ◽  
Vol 65 (4) ◽  
pp. R65-R76 ◽  
Author(s):  
Rachel Njeim ◽  
William S Azar ◽  
Angie H Fares ◽  
Sami T Azar ◽  
Hala Kfoury Kassouf ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cell Death ◽  
Diabetic Kidney Disease ◽  
Diabetic Patients ◽  
Impaired Wound Healing ◽  
Glucose Levels ◽  
Patients With Diabetes

NETosis, a novel form of neutrophil-related cell death, acts as a major regulator of diabetes and diabetes-associated complications. In this review, we show that the extrusion of neutrophil extracellular traps, termed NETs, plays an important role in the pathogenesis of type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and diabetes-induced complications. In T1DM, β-cell death induces the sequestration of neutrophils in the pancreas and seems to be correlated with increased NETosis. In T2DM patients, products of NETs release are significantly elevated. Increased levels of dsDNA are correlated with the presence of cardiovascular disease and diabetic kidney disease, further supporting the role of NETosis in the pathogenesis of other diabetes-induced complications such as impaired wound healing and diabetic retinopathy. NETosis is induced by high glucose through incompletely understood mechanisms, but it also appears to be elevated in patients with diabetes who have tightly controlled glucose levels. We hypothesize that hyperglycemia worsens the already elevated baseline of NETosis in diabetic patients to further increase its detrimental effects.

scholarly journals Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Peter Bramlage ◽  
Stefanie Lanzinger ◽  
Sascha R. Tittel ◽  
Eva Hess ◽  
Simon Fahrner ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Clinical Practice ◽  
Kidney Disease ◽  
Analysis Data ◽  
Disease Diagnosis ◽  
Diabetic Patients ◽  
European Society Of Cardiology

Abstract Background Recent European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines provide recommendations for detecting and treating chronic kidney disease (CKD) in diabetic patients. We compared clinical practice with guidelines to determine areas for improvement. Methods German database analysis of 675,628 patients with type 1 or type 2 diabetes, with 134,395 included in this analysis. Data were compared with ESC/EASD recommendations. Results This analysis included 17,649 and 116,747 patients with type 1 and type 2 diabetes, respectively. The analysis showed that 44.1 and 49.1 % patients with type 1 and type 2 diabetes, respectively, were annually screened for CKD. Despite anti-diabetic treatment, only 27.2 % patients with type 1 and 43.5 % patients with type 2 achieved a target HbA1c of < 7.0 %. Use of sodium-glucose transport protein 2 inhibitors (1.5 % type 1/8.7 % type 2 diabetes) and glucagon-like peptide-1 receptor agonists (0.6 % type 1/5.2 % type 2 diabetes) was limited. Hypertension was controlled according to guidelines in 41.1 and 67.7 % patients aged 18–65 years with type 1 and 2 diabetes, respectively, (62.4 vs. 68.4 % in patients > 65 years). Renin angiotensin aldosterone inhibitors were used in 24.0 and 40.9 % patients with type 1 diabetes (micro- vs. macroalbuminuria) and 39.9 and 47.7 %, respectively, in type 2 diabetes. Conclusions Data indicate there is room for improvement in caring for diabetic patients with respect to renal disease diagnosis and treatment. While specific and potentially clinically justified reasons for non-compliance exist, the data may serve well for a critical appraisal of clinical practice decisions.

scholarly journals Body Mass Index, Fasting Plasma Glucose Levels, and C-peptide Levels as Predictors of the Future Insulin Use in Japanese Type 2 Diabetic Patients

2010 ◽  
Vol 57 (3) ◽  
pp. 237-244 ◽  
Author(s):  
Atsushi GOTO ◽  
Maki TAKAICHI ◽  
Miyako KISHIMOTO ◽  
Yoshihiko TAKAHASHI ◽  
Hiroshi KAJIO ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
C Peptide ◽  
Glucose Levels ◽  
Insulin Use ◽  
Type 2 Diabetic

scholarly journals Association of Plasma Myeloperoxidase Level with Risk of Coronary Artery Disease in Patients with Type 2 Diabetes

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Ping Song ◽  
Jin Xu ◽  
Yongfeng Song ◽  
Shiliang Jiang ◽  
Haitao Yuan ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Linear Regression Analysis ◽  
Multiple Linear Regression Analysis ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Logistic Analysis ◽  
Artery Disease

Aims. This study aimed to investigate whether the change of plasma myeloperoxidase (MPO) level would be associated with the incidence of coronary artery disease (CAD) among diabetic patients.Methods. 339 patients with type 2 diabetes mellitus (DM) underwent coronary angiography. Of them, 204 cases had CAD and were assigned to CAD group and 135 cases without CAD were assigned to non-CAD group.Results. Compared to non-CAD group, CAD group had higher level of plasma MPO (p<0.01). Multiple linear regression analysis showed that plasma MPO level was correlated with Gensini score. Multiple logistic analysis showed that the odds ratios for CAD across increasing tertiles of MPO level were 1.191 (0.971–1.547) and 1.488 (1.115–2.228) (p=0.048,p=0.009versus 1st tertile of MPO level, resp.) by adjusting for age, sex, and other conventional risk factors for CAD. The subjects were stratified into nine groups according to tertiles of MPO and HbA1c. The odds ratio for CAD was significantly higher in group with highest levels of MPO and HbA1c (OR = 4.08,p<0.01).Conclusion. Plasma MPO level was positively correlated with the degree of coronary artery stenosis in type 2 diabetic patients, and increasing blood glucose might amplify the association between MPO and CAD.

Sign in / Sign up

Export Citation Format

Share Document